BioAlliance Pharma and Teva announce first license agreement for Sitavig® for Israel

Paris, June 13, 2012 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to oncology orphan products and specialty products today announces the signature of an exclusive license agreement for Sitavig® (Acyclovir Lauriad™) with Abic Marketing Limited ("Teva"), a group subsidiary of Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) for commercialization rights in Israel.

BioAlliance Pharma has conceived and developed Sitavig® for the treatment of recurrent labial herpes in immunocompetent patients presenting more than 4 episodes a year. Sitavig® is based on the innovative mucoadhesive buccal technology Lauriad™, delivering very high concentrations of acyclovir at the site of herpes infection. The phase III trial (775 patients) has shown a strong efficacy and safety profile, basis for the registration submission.

Financial terms of this license agreement are not publicly disclosed. This agreement includes upfront and milestone payments as well as royalties on sales in Israel, to be paid to BioAlliance Pharma by Teva.

« *This license agreement with Teva is a major step for Sitavig® as it acknowledges the interest and the commercial potential of this innovative product",* declared Judith Greciet, CEO of BioAlliance Pharma. *"Teva as the leading player on Israeli market is a key partner for BioAlliance and for the commercialization of Sitavig®, and we look forward to build a constructive and close partnership",* added Judith Greciet.

About Sitavig®

BioAlliance Pharma has conceived and developed Sitavig® for the treatment of recurrent orofacial herpes in immunocompetent patients. The product is an innovative mucoadhesive buccal tablet delivering very high concentrations of the active ingredient in mucosa and lips, sites of the herpes infection.

The efficacy of Sitavig® has been validated with a pivotal phase III clinical trial conducted in 775 patients that showed a significant reduction in the occurrence of vesicular lesions (p=0.043), in the time to healing of vesicular lesions (p=0.015), in the herpes episode duration (p=0.0038) and in the severity of symptoms(p=0.008). Moreover, a 9-month follow-up showed that Sitavig® had an effect on the long term, delaying the time to occurrence of the following herpes episode (p=0.04).

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir®/Sitavig® (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

Oncology Orphan products

Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going

Validive® (Clonidine Lauriad™) (mucositis): Phase II on going

AMEP® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2011 Reference Document filed with the AMF on April 24, 2012, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 76 00
judith.greciet@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com